Novartis Pays $55M Upfront for Kyorin's Preclinical MRGPRX2 Antagonist KRP-M223 in $832.5M Global Deal

On March 3, Japanese biotechnology company Kyorin Pharmaceutical (hereinafter referred to as "Kyorin Pharmaceutical") announced that it had reached an agreement with Novartis regarding its discovery.Preclinical PipelineKRP-M223 and its backup compoundsReach a global licensing agreement.

In return, Xinglin PharmaceuticalWill Obtain$55 million(approximately 400 million yuan) as an upfront payment and is eligible to receive up to$777.5 million in milestone payments, as well as tiered royalties on net sales,The total potential deal amount is $832.5 million (approximately 6.063 billion yuan).

According to the agreement, Novartis will obtainDevelopment, Manufacturing and CommercializationNovartis has obtained the exclusive global license for KRP-M223 and holds the option to co-promote and commercialize the drug in Japan with Kyorin Pharmaceutical. Meanwhile, Kyorin Pharmaceutical retains the option to commercialize and manufacture the product for the Japanese market in Japan. Currently, KRP-M223 is in the preclinical development stage led by Kyorin Pharmaceutical, and subsequent global development will be advanced by Novartis.

$600 Million for a Preclinical PipelineBehind, isNovartisIn immune diseasesFieldFaced withPatent CrisisAnd the next tier of product layout.

Chronic Spontaneous Urticaria (CSU) refers to the occurrence of wheals either daily or intermittently without any identifiable cause, lasting for more than 6 weeks. It is most commonly seen in women aged 30-50, and 66% of patients experience symptoms that persist for at least 3 years.

According to the "White Paper on the Disease Burden of Chinese Patients with Chronic Spontaneous Urticaria,"The incidence of chronic urticaria worldwide is approximately 0.05.% to 3%, of which about 1% in China, and CSU accounts for approximately 68%. The main clinical manifestations are wheals and pruritus, with 30% accompanied by angioedema.In addition to skin damage, CSU can also cause deeper systemic effects, increasing the risk of autoimmune diseases and cancer.

There is currently no curative therapy for chronic spontaneous urticaria. After first-line antihistamine drugsAfter treatment, about 60% of patients were poorly controlled., and there has been a lack of reliable subsequent treatment options in the past, with extremely high unmet clinical needs.

In terms of market size, the global chronic spontaneous urticaria (CSU) market reached USD 779.28 million in 2024 and is expected to reach USD 1,541.41 million by 2032, with a compound annual growth rate (CAGR) of 8.90% from 2025 to 2032. With the deepening understanding of CSU and the increasing demand for treatment, this market is expected to maintain its growth momentum in the coming years.

According to Kyorin Pharmaceutical, KRP-M223 is an MRGPRX2 antagonist. By blocking the activation of MRGPRX2 and the degranulation of mast cells, MRGPRX2 antagonists have the potential to broadly treat mast cell-mediated diseases, including allergic and inflammatory conditions involving mast cells, such as chronic spontaneous urticaria.

MRGPRX2 is a G protein-coupled receptor expressed on mast cells found in barrier tissues (such as the skin, airways, and gastrointestinal tract), which are activated by many ligands, including numerous peptides released from sensory neurons and other cell types. In response to MRGPRX2 activation, mast cells degranulate and release histamine, tryptase, chymase, chemokines, and cytokines, thereby triggering urticaria itching, angioedema, type 2 inflammation (through the involvement of the adaptive immune system), as well as chronic itching and pain.

Notably, globally, only two MRGPRX2 antagonists have entered clinical trials: EVO756 (Evommune) and INCB000262 (Incyte Corporation). Among them, INCB000262 is being developed for the treatment of chronic spontaneous urticaria.Phase II ClinicalAnnounced Suspension in 2024Enrollment was halted due to signals observed in preclinical in vivo toxicology studies. However, another proof-of-concept clinical trial has completed enrollment, and its clinical data will guide future clinical development plans as well as inform potential strategies for developing alternative molecules.

Few Biotech Bets, Preclinical In Vivo Toxicology Signals Raise Questions: MRGPR Antagonist Development Carries Significant Risks. Why Did Novartis Still Pay $400 Million Upfront for This Preclinical Pipeline?

The primary reason is that good news has come from the market and clinical front.Pioneer of MRGPR Antagonists, Evommune, Focused on Developing Treatments for Immune-Mediated Inflammatory Diseases, Announces Positive Results from the Phase 1 Proof-of-Concept Study of MRGPRX2 Antagonist EVO756 in July 2024. The proof-of-concept trial data exceeded Evommune's expectations, and...StartMultiple clinical trials of EVO756, including a Phase 2b study in patients with chronic spontaneous urticaria (CSU) conducted in the first half of 2025. By blocking MRGPRX2 activation and degranulation in mast cells,EVO756 may become a treatment for various mast cell-mediated diseasesFirst-In-CLass oral therapeutic drug.

Notably, Evommune also carries the halo of being a "star company" in skin-related innovative drug development — just one week before founding Evommune, its founder Luis Peña had sold his previously established dermatology drug development company to Eli Lilly for $1.1 billion. Three months after the public release of its proof-of-concept data, Evommune announced the completion of a $115 million (approximately RMB 819 million) Series C financing round.

The deeper reason is that Novartis is building a next-generation blockbuster drug pipeline to solidify its "throne" as the global leader in chronic spontaneous urticaria.In 2014, Xolair, a collaboration between Novartis and Roche, received FDA approval as a treatment for chronic urticaria. Xolair is an anti-IgE medication that specifically targets, binds to, and blocks IgE. By reducing free IgE, downregulating high-affinity IgE receptors, and limiting mast cell degranulation, it minimizes the release of mediators during the allergic inflammation cascade.

As one of the two core autoimmune products of Novartis, Xolair has been approved in multiple countries for various indications, including moderate to severe persistent allergic asthma (SAA), chronic spontaneous urticaria (CSU), chronic idiopathic urticaria (CIU), and nasal polyps (CRSwNP). In China, Xolair was approved in August 2017 as the first targeted drug for asthma treatment. According to Novartis' financial report,Xolair Revenue Reached $1.463 Billion in 2023, a 7% Year-over-Year Increase。However, the compound patent for Xolair has already expired, and its formulation patent is set to expire in November 2025.

At the same time, Cosentyx, the IL-17A monoclonal antibody that dominates the vast markets of psoriasis and rheumatoid diseases, is also about to face a critical patent expiration in 2025/2026.Facing the dilemma of expiring patents and pursued by major MNCs, Novartis is encountering increasingly fierce competition in the field of immunological diseases: Sanofi and Genentech's IL-4Rα monoclonal antibody Dupixent, as well as Eli Lilly's IL-17A monoclonal antibody Taltz, are both strong competitors.

Betting on the next generation of therapies and continuously advancing targeted drugs is clearly Novartis' long-term strategy in the autoimmune disease field, and it is about to pay off.

In May 2024, Novartis announcedOralLong-term Efficacy and Safety Data of BTK Inhibitor Remibrutinib. The data shows that for patients with chronic spontaneous urticaria who still have symptoms while using second-generation H1-antihistamines, remibrutinib demonstrated significant symptom improvement early in treatment (with UAS7 improvement observed as early as the first week) and sustained through week 52 (1 year). The evaluation at week 52 showed that nearly half of the patients had no itching or hives at all (UAS7=0).

Early Month, Center for Drug Evaluation, National Medical Products Administration of China (CDE) Official website announced that Novartis has filed a new drug application for Remibrutinib Tablets (RThe marketing application for Emibrutinib has been accepted., the guessed indication is Chronic Spontaneous Urticaria (CSU).. This isREmibrutinib submitted for marketing authorization for the first time globally。

If successfully approved for marketing, remibrutinib will not only becomeThe world's first BTK inhibitor to cover the CSU indication will also fill the gap in oral targeted drugs for CSU, shifting CSU treatment from "broad-spectrum suppression" to "precise targeting."